BFEC
BMRN icon

Benjamin F. Edwards & Company’s BioMarin Pharmaceuticals BMRN Stock Holding History

Benjamin F. Edwards & Company’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$32K Sell
391
-3
-0.8% -$250 ﹤0.01% 1435
2024
Q1 		$35K Sell
394
-39
-9% -$3.49K ﹤0.01% 1395
2023
Q4 		$42K Buy
433
+249
+135% +$22K ﹤0.01% 1293
2023
Q3 		$16K Sell
184
-44
-19% -$3.92K ﹤0.01% 1293
2023
Q2 		$20K Hold
228
– – ﹤0.01% 1276
2023
Q1 		$22K Sell
228
-18
-7% -$1.87K ﹤0.01% 1252
2022
Q4 		$25K Buy
246
+43
+21% +$4.04K ﹤0.01% 1230
2022
Q3 		$17K Sell
203
-1,026
-83% -$91.4K ﹤0.01% 1292
2022
Q2 		$102K Sell
1,229
-1,526
-55% -$122K ﹤0.01% 850
2022
Q1 		$212K Sell
2,755
-758
-22% -$63.4K 0.01% 671
2021
Q4 		$310K Buy
3,513
+286
+9% +$23.6K 0.01% 571
2021
Q3 		$249K Sell
3,227
-680
-17% -$53.7K 0.01% 603
2021
Q2 		$326K Sell
3,907
-168
-4% -$13.3K 0.02% 529
2021
Q1 		$308K Buy
4,075
+1,012
+33% +$82.7K 0.02% 570
2020
Q4 		$269K Buy
3,063
+1,542
+101% +$122K 0.02% 560
2020
Q3 		$116K Buy
1,521
+314
+26% +$31.8K 0.01% 708
2020
Q2 		$149K Buy
1,207
+1,188
+6,253% +$118K 0.01% 638
2020
Q1 		$2K Hold
19
– – ﹤0.01% 1578
2019
Q4 		$2K Sell
19
-920
-98% -$69.5K ﹤0.01% 1756
2019
Q3 		$63K Buy
939
+893
+1,941% +$68.8K ﹤0.01% 857
2019
Q2 		$4K Buy
46
+19
+70% +$1.63K ﹤0.01% 1660
2019
Q1 		$2K Hold
27
– – ﹤0.01% 1600
2018
Q4 		$2K Hold
27
– – ﹤0.01% 1588
2018
Q3 		$3K Hold
27
– – ﹤0.01% 1467
2018
Q2 		$3K Hold
27
– – ﹤0.01% 1465
2018
Q1 		$2K Hold
27
– – ﹤0.01% 1509
2017
Q4 		$2K Sell
27
-15
-36% -$1.3K ﹤0.01% 1474
2017
Q3 		$4K Hold
42
– – ﹤0.01% 1341
2017
Q2 		$4K Buy
+42
New +$3.82K ﹤0.01% 1266

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Benjamin F. Edwards & Company's BMRN Position: Q2 2024 in Review

Benjamin F. Edwards & Company reduced its BioMarin Pharmaceuticals (BMRN) stake by 0.76% in Q2 2024, selling an estimated $250 and leaving 391 shares worth $32K. The position accounts for ﹤0.01% of the portfolio, ranked #1435.

Benjamin F. Edwards & Company first reported a position in BMRN in Q2 2017 and has held it in 29 quarters since. The position peaked at $326K in Q2 2021. 560 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

  • Benjamin F. Edwards & Company held 391 shares of BioMarin Pharmaceuticals worth $32K as of Q2 2024.
  • Benjamin F. Edwards & Company sold 3 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $250.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #1435 holding.
  • Benjamin F. Edwards & Company first reported a position in BioMarin Pharmaceuticals in Q2 2017 and has held it in 29 quarters since.
  • Benjamin F. Edwards & Company's BioMarin Pharmaceuticals position peaked at $326K in Q2 2021.
  • 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.